Y-mAbs Therapeutics Stock (NASDAQ:YMAB)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$10.86

52W Range

$5.29 - $20.90

50D Avg

$13.93

200D Avg

$13.80

Market Cap

$472.08M

Avg Vol (3M)

$262.49K

Beta

0.67

Div Yield

-

YMAB Company Profile


Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

100

IPO Date

Sep 21, 2018

Website

YMAB Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
License$500.00K$16.00M$2.00M
Product$84.32M$49.27M$32.90M

Fiscal year ends in Dec 23 | Currency in USD

YMAB Financial Summary


Dec 23Dec 22Dec 21
Revenue$84.82M$65.27M$34.90M
Operating Income$-25.67M$-94.81M$-115.43M
Net Income$-21.43M$-96.33M$-56.34M
EBITDA$-25.67M$-94.81M$-115.43M
Basic EPS-$-2.20$-1.30
Diluted EPS-$-2.20$-1.30

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 08, 24 | 1:58 PM
Q2 24Aug 12, 24 | 11:20 AM
Q1 24May 08, 24 | 12:00 AM

Peer Comparison


TickerCompany
VECTVectivBio Holding AG
ZNTLZentalis Pharmaceuticals, Inc.
RVMDRevolution Medicines, Inc. Warrant
MRUSMerus N.V.
LRMRLarimar Therapeutics, Inc.
DAWNDay One Biopharmaceuticals, Inc.
EWTXEdgewise Therapeutics, Inc.
ERASErasca, Inc.
BLUEbluebird bio, Inc.
TVTXTravere Therapeutics, Inc.
STROSutro Biopharma, Inc.
BDTXBlack Diamond Therapeutics, Inc.
GBIOGeneration Bio Co.
ARQTArcutis Biotherapeutics, Inc.
BCELAtreca, Inc.
SNDXSyndax Pharmaceuticals, Inc.
KRONKronos Bio, Inc.
PASGPassage Bio, Inc.
CCCCC4 Therapeutics, Inc.
MRSNMersana Therapeutics, Inc.
PCVXVaxcyte, Inc.
MIRMMirum Pharmaceuticals, Inc.